Among patients with diabetes who require in-center hemodialysis, the use of GLP-1 receptor agonists is associated with a lower risk of developing Alzheimer disease and related dementias compared with ...

GLP-1 RAs show greater cardiovascular benefits in type 2 diabetes patients with BMI ≥25 compared to DPP-4 inhibitors. Kidney protection from GLP-1 RAs remains consistent across all BMI categories. The ...

Those prescribed a GLP-1 RA had a significantly increased risk for new chronic cough compared with those prescribed any non-GLP-1 RA second-line medication, DPP-4 inhibitor, or sulfonylurea in a ...

GLP-1 drugs show a potential link to reduced epilepsy risk in people with type 2 diabetes. People taking GLP-1 drugs were 16% less likely to develop epilepsy than those on DPP-4 inhibitors.

Relative to GLP-1RA and DPP-4 inhibitor use, SGLT2 inhibitor use was associated with an increased risk for erythrocytosis but not an increased risk for thrombosis in T2D. Among individuals with type 2 ...